U

Universitair Ziekenhuis Leuven | Hematology Department

Research site
(Unclaimed)
Location
Herestraat 49, Leuven, Vlaams-Brabant, Belgium
Site insights

Top conditions

Ulcerative Colitis (12 trials)

Ulcer (12 trials)

Colitis (12 trials)

Crohn Disease (9 trials)

Breast Cancer (5 trials)

Top treatments

Upadacitinib
ABT-494
Risankizumab
Filgotinib
Cyclosporine A
Daratumumab
Cyclophosphamide
Carboplatin
Sacituzumab
ABBV-8E12

Parent organization

This site is a part of Universitair Ziekenhuis Leuven

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

47 of 115
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Feasibility Study Evaluating the Performance of Focused Multipolar Stimulation and Sound Coding in Adults. (SASC)

The purpose of this early feasibility study is to explore several facets of hearing performance that may show improvements for alternative modes of s...

Enrolling
Hearing Impairment, Sensorineural
Device: Focused Multipolar Stimulation (FMS) strategy

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Risankizumab
Biological: Placebo

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as mon...

Active, not recruiting
Metastatic Colorectal Cancer
Drug: Standard of Care
Drug: Botensilimab

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Enrolling
Colitis, Ulcerative
Drug: JNJ-77242113
Drug: Placebo

This study is for young children with severe hemophilia A who have previously not been treated with BAX855 or other FVIII concentrates.The main aim o...

Active, not recruiting
Hemophilia A
Biological: PEGylated Recombinant Factor VIII
Biological: ITI

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in comb...

Enrolling
Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

The study consists of 4 sub-studies, as follows:Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety...

Active, not recruiting
Crohn's Disease
Drug: Risankizumab SC
Drug: Risankizumab On-Body Injector (OBI)

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: risankizumab
Drug: placebo for risankizumab
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Rituximab

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.The main objectives o...

Active, not recruiting
Spondyloarthritis
Drug: Placebo
Drug: Upadacitinib

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared...

Active, not recruiting
Amyloidosis
Drug: Cyclophosphamide
Drug: Daratumumab

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Drug: Upadacitinib
Other: Placebo

The purpose of this study is to evaluate the safety in mother and neonate/infant of M281 administered to pregnant women who are at high risk for Earl...

Active, not recruiting
Hemolytic Disease of the Fetus and Newborn
Drug: M281

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-d...

Active, not recruiting
Gastro-enteropancreatic Neuroendocrine Tumor
Drug: Lanreotide ATG
Drug: CAM2029

This study is researching an investigational drug called REGN5668. Participants will receive additional investigational drugs in combination with REG...

Enrolling
Endometrial Cancer
Primary Peritoneal Cancer
Drug: Sarilumab
Drug: REGN4018

This is a phase 2 study to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Dela...

Enrolling
Delayed Graft Function
Other: Placebo
Biological: ARGX-117

Trial sponsors

AbbVie logo

AbbVie (34 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems